- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00770718
Factor VII, Prothrombin Complex Concentrate, and Fresh Frozen Plasma in Warfarin-Related Intracranial Hemorrhage
A Comparison of Recombinant Activated Factor VII, Prothrombin Complex Concentrate, and Fresh Frozen Plasma for Anticoagulation Reversal in Warfarin-Associated Acute Intracranial Hemorrhage: A Dose Ranging Pilot Study
Study Overview
Status
Conditions
Detailed Description
Both recombinant activated Factor VIIa (rFVIIa) as well as Prothrombin Complex Concentrate (PCC) are labeled for the treatment of bleeding episodes in patients with hemophilia. Many hospitals are also using each for the following unlabeled indications: bleeding rescue in surgical patients, severe multiple trauma with ongoing bleeding, intracranial bleeding < 4 hours since symptom onset, traumatic head injury with evidence of expanding bleed, retroperitoneal bleed, and life-threatening bleeding due to idiopathic coagulopathy. To our knowledge, these two products have never been clinically compared head to head for the reversal of warfarin in the setting of intracranial hemorrhage.
The rFVIIa (Novoseven) guidelines are based off of national data and utilize a dose range of 40-90 mcg/kg of ideal body weight (2.8-6.3 mg for a 70 kg. patient) with an additional dose if needed. The dose cited in the literature for the management of intracerebral bleeds ranges from 10 to 120 mcg/kg (0.7 - 8.4 mg for a 70 kg. patient,) with higher doses associated with increased risk of thromboembolic events.
The recommended dosing of PCC is 30-50 i.u. per kilogram of ideal body weight with additional dosing if needed. PCC (Profilnine®SD) is a mixture of the following vitamin K-dependent clotting factors: II (prothrombin), VII (proconvertin), IX (plasma thromboplastin component; PTC; Christmas factor), and X (Stuart-Prower factor). These factors are required for the conversion of prothrombin to thrombin and thus adequate hemostasis, and are synthesized in the liver.
Currently at the most hospitals around the country, fresh frozen plasma (FFP) is the mainstay for reversal of warfarin-related coagulopathy in intracranial hemorrhage at the discretion of the treating attending physician. We propose to study all the current reversal practices in the intracranial hemorrhage population here at the University of Utah as part of a quality improvement project for both patient safety and cost.
We will perform a safety and feasibility study comparing dosage regimens of rFVIIa, FIXa and fresh frozen plasma (FFP) infusion in the normalization of coagulopathy in the context of warfarin-related intracerebral hemorrhage. Our primary outcome is time to INR normalization defined as INR≤ 1.3 on two consecutive readings separated by 2 hours.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Non-traumatic intracranial hemorrhage (subdural or intraparenchymal)
- Known warfarin ingestion
- INR ≥2.0
- GCS <13
Exclusion Criteria:
- Pregnancy
- History of venous thrombosis or pulmonary embolus
- Acute myocardial infarction
- Acute stroke
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Recombinant Activated Factor VII
The first five patients who meet the selection criteria will be administered an intravenous dose of rFVIIa 1mg upon arrival.
INR will be drawn at 20 minutes post-rFVIIa administration.
If normalized (≤1.3), then repeat INR with be drawn every 2 hours thereafter for 6 hours total, and again at 24 hours after initial administration.
If at any time, the INR is >1.3, then rFVIIa 1mg will be readministered and the INR will again be checked 20 minutes after administration and every 2 hours for 6 hours total and again at 24 hours post-administration.
This may be repeated until a total dose of 80mcg/kg has been given.
If a maximum total of 80mcg/kg has been administered without successful correction of INR, then FFP infusions will be utilized to complete correction.
|
Five patients who meet the selection criteria will be administered an intravenous dose of rFVIIa 1mg upon arrival.
INR will be drawn at 20 minutes post-rFVIIa administration.
If normalized (≤1.3), then repeat INR with be drawn every 2 hours thereafter for 6 hours total, and again at 24 hours after initial administration.
If at any time, the INR is >1.3, then rFVIIa 1mg will be readministered and the INR will again be checked 20 minutes after administration and every 2 hours for 6 hours total and again at 24 hours post-administration.
This may be repeated until a total dose of 80mcg/kg has been given.
Other Names:
|
EXPERIMENTAL: Prothrombin Complex Concentrate (PCC)
5 patients will receive PCC based on ideal body weight.
Each patient will receive 30 i.u./kg ideal body weight as is rounded to the nearest dispensed vial size.
Vials are dispensed as 5mL (500 i.u.), 10mL (1000 i.u.), or 10mL (1500i.u.).
INR will be drawn at 20 minutes post-administration and, if normalized (≤1.3), 2 hours post-administration and every 2 hours for 6 hours total.
The INR will also be checked 24 hours post-administration.
If at any time, the INR is >1.3, then PCC will be readministered at the same dose and the INR will again be checked 20 minutes after administration and every 2 hours for 6 hours total and again at 24 hours post-administration.
A maximum total of 60 iu/kg can be administered before FFP will be used to complete the correction.
|
5 patients will receive PCC based on ideal body weight.
Each patient will receive 30 i.u./kg ideal body weight as is rounded to the nearest dispensed vial size.
Vials are dispensed as 5mL (500 i.u.), 10mL (1000 i.u.), or 10mL (1500i.u.).
INR will be drawn at 20 minutes post-administration and, if normalized (≤1.3), 2 hours post-administration and every 2 hours for 6 hours total.
The INR will also be checked 24 hours post-administration.
If at any time, the INR is >1.3, then PCC will be readministered at the same dose and the INR will again be checked 20 minutes after administration and every 2 hours for 6 hours total and again at 24 hours post-administration.
A maximum total of 60 iu/kg can be administered.
Other Names:
|
ACTIVE_COMPARATOR: Fresh Frozen Plasma (FFP)
The last five patients will receive transfusions of FFP to normalize INR.
If the initial INR is between 2-4, then 2 units of FFP (Round 1) will be administered emergently.
If the initial INR is >4, then 4 units of FFP will be administered (Round 1).
The INR will be checked after each round of FFP infusion completed.
Once INR ≤1.3, then the INR will be again checked every 2 hours after normalization for 6 hours total and then 24 hours post-initial infusion.
If the INR should ever return to >1.3, then repeat infusions of FFP will begin as outlined above and the INR will be checked serially as defined above.
|
Five patients will receive transfusions of FFP to normalize INR.
If the initial INR is between 2-4, then 2 units of FFP (Round 1) will be administered emergently.
If the initial INR is >4, then 4 units of FFP will be administered (Round 1).
The INR will be checked after each round of FFP infusion completed.
Once INR ≤1.3, then the INR will be again checked every 2 hours after normalization for 6 hours total and then 24 hours post-initial infusion.
If the INR should ever return to >1.3, then repeat infusions of FFP will begin as outlined above and the INR will be checked serially as defined above.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Normalization of INR (<1.4)
Time Frame: 20min, 2hrs, 4hrs, 6hrs, 24hrs
|
20min, 2hrs, 4hrs, 6hrs, 24hrs
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Hematoma progression
Time Frame: 24hrs
|
24hrs
|
Neurological status
Time Frame: 24hrs & 1month
|
24hrs & 1month
|
Timing of intervention completion
Time Frame: 24hrs
|
24hrs
|
Dosing of intervention required
Time Frame: 24hrs
|
24hrs
|
Medical complications during hospitalization
Time Frame: days
|
days
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 21152 (Other Identifier: City of Hope Comprehensive Cancer Center)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Intracranial Hemorrhage
-
Walton Centre NHS Foundation TrustUniversity of Liverpool; National Institute for Health Research, United KingdomNot yet recruitingTiming to Restart Direct Oral Anticoagulants After Traumatic Intracranial Haemorrhage (RESTARTtlCrH)Traumatic Intracranial Haemorrhage
-
McMaster UniversityCanadian Institutes of Health Research (CIHR)CompletedTraumatic Intracranial HaemorrhageCanada
-
McMaster UniversityCanadian Institutes of Health Research (CIHR)UnknownTraumatic Intracranial HaemorrhageCanada
-
Chinese PLA General HospitalThe First Affiliated Hospital of Nanchang University; First Affiliated Hospital... and other collaboratorsCompletedIntracranial Hemorrhage, HypertensiveChina
-
University Hospital, GrenobleUnknownIntracranial Hemorrhage, HypertensiveFrance
-
Hans GranhedChalmers University of Technology; Medfield DiagnosticsCompletedTraumatic Intracranial HemorrhageSweden
-
University of UtahWithdrawnIntracranial Hemorrhage, Traumatic | Intracranial Hemorrhage, SpontaneousUnited States
-
University of Texas at AustinNot yet recruitingTraumatic Intracranial Hemorrhage
-
University of Texas at AustinUniversity of KansasNot yet recruitingAnticoagulants; Increased
-
University of Texas at AustinNot yet recruitingHemorrhage | Bleeding | Trauma | Intracranial HemorrhagesUnited States
Clinical Trials on Recombinant Activated Factor VII (rFVIIa)
-
Joseph Broderick, MDNovo Nordisk A/S; National Institute of Neurological Disorders and Stroke (NINDS)RecruitingIntracerebral HemorrhageUnited States, Canada, Germany, Japan, Spain, United Kingdom
-
Novo Nordisk A/SCompletedCongenital Bleeding Disorder | Haemophilia A | Haemophilia BUnited Kingdom
-
Novo Nordisk A/SCompletedCongenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With InhibitorsFrance, United States, Sweden, Serbia, Turkey, United Kingdom, Malaysia, Brazil, Former Serbia and Montenegro, Japan, South Africa
-
Universiti Sains MalaysiaCompletedMassive Hemorrhage | Massive Blood Loss | Massive Blood Transfusion; ThrombocytopeniaMalaysia
-
Novo Nordisk A/SCompletedTrauma | Acquired Bleeding DisorderUnited States, Canada
-
Novo Nordisk A/SCompletedHealthy | Congenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors | Acquired Bleeding Disorder | Acquired Haemophilia | Congenital FVII Deficiency | Glanzmann's DiseaseFrance
-
Novo Nordisk A/SCompletedAcquired Bleeding Disorder | Intracerebral HaemorrhageSpain, Sweden, Singapore, Norway, Italy, Switzerland, Australia, Austria, Belgium, Canada, Denmark, Finland, Germany, Netherlands, United Kingdom
-
Novo Nordisk A/SCompletedHealthy | Congenital Bleeding DisorderUnited States
-
Novo Nordisk A/SCompletedCongenital Bleeding Disorder | Haemophilia A | Haemophilia BFrance, Israel, Germany
-
Novo Nordisk A/SCompletedOther Haemostasis Disorder | Haemorrhagic CystitisUnited States